Undisclosed etiotropic preparation
/ Federal Medical Biological Agency
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 02, 2023
Treatment of COVID-19 patients with a SARS-CoV-2-specific siRNA-peptide dendrimer formulation.
(PubMed, Allergy)
- P2 | "MIR 19 ®, a SARS-CoV-2-specific siRNA-peptide dendrimer formulation is safe, well tolerated and significantly reduces time to clinical improvement in patients hospitalized with moderate COVID-19 compared to standard therapy in a randomized controlled trial."
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1